















W.M.BA systematic review of the safety and efficacy of currently
used treatment modalities in the treatment of patients
with PIK3CA-related overgrowth spectrumSarah M. Bernhard, MD,a Luise Adam, MD,a,b Hady Atef, PhD,c,d Dario Häberli, MD,a Wichor M. Bramer, PhD,e
Beatrice Minder, MA,f Yvonne Döring, PhD,a,g,h Jessica E. Laine, PhD,a,d Taulant Muka, MD, PhD,d
Jochen Rössler, MD,i and Iris Baumgartner, MD,a Bern, Switzerland; Cairo, Egypt; Rotterdam, The Netherlands; and
Munich, GermanyABSTRACT
Background: PIK3CA (activating mutations of the p110a subunit of phosphatidylinositol 3-kinases)-related overgrowth
spectrums (PROS) include a variety of clinical presentations that are associated with hypertrophy of different parts of the
body. We performed a systematic literature review to assess the current treatment options and their efficacy and safety
for PROS.
Methods: A literature search was performed in Embase, MEDLINE (Ovid), Web of Science Core Collection, Cochrane
Central Register of Controlled Trials, ClinicalTrials.gov, and Google Scholar to retrieve studies on the treatment of hy-
pertrophy in PROS. Randomized controlled trials, cohort studies, and case series with $10 patients were included in the
present review. The titles, abstracts, and full text were assessed by two reviewers independently. The risk of bias was
assessed using the Newcastle-Ottawa scale.
Results: We included 16 studies of the treatment of hypertrophy in PROS patients, 13 (81.3%) from clinical retrospective
studies and 3 (13.7%) from prospective cohort studies. The risk of bias grade was low for 2, medium for 12, and high for 2
studies. Of the 16 studies, 13 reported on surgical treatment and 3 reported pharmacologic treatment using phospha-
tidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway inhibitors in PROS patients. In 3 studies,
PROS was defined by a mutation in the PIK3CA gene, and 13 studies relied on a clinical definition of PROS. Surgical
therapy was beneficial for a specific subgroup of PROS (macrodactyly). However, little has been reported concerning
surgery and the potential benefits for other PROS entities. The reported side effects after surgical therapy were mostly
prolonged wound healing or scarring. PI3K/mTOR pathway inhibition was beneficial in patients with PROS by reducing
hypertrophy and systemic symptoms. The adverse effects reported included infection, changes in blood count, liver
enzymes, and metabolic measures.
Conclusions: Surgery is a locally limited treatment option for specific types of PROS. A promising treatment option for
PROS is pharmacologic PIK3CA inhibition. However, the level of evidence on the treatment of overgrowth in PROS
patients is limited. (J Vasc Surg Venous Lymphat Disord 2021;-:1-12.)
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d Type of Research: A systematic literature review on
the safety and efficacy of currently used treatment
modalities in the management of patients with
PIK3CA (activating mutations of the p110a subunit
of phosphatidylinositol 3-kinases)-related over-
growth spectrum (PROS)
d Key Findings: We included 13 retrospective studies
and 3 prospective cohort studies on the treatment
of hypertrophy in PROS. Of these studies, 13 reported
on surgical treatment and 3 on pharmacological
treatment using phosphatidylinositol-3-kinase
(PI3K)/mammalian target of rapamycin (mTOR)
pathway inhibitors. Surgical therapy was beneficial
in patients with macrodactyly, and PI3K/mTOR
pathway inhibition was beneficial for patients with
all types of with PROS.
d Take Home Message: Surgery is a locally limited
treatment option suitable for specific types of
PROS. A promising treatment option for PROS is
pharmacological PIK3CA inhibition using PI3K/
mTOR pathway inhibitors.
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--- 2021Somatic activating mutations of the phosphatidylinosi-
tol-3-kinase (PI3K)/AKT (protein kinase B)/mTOR pathway
lead to angiogenesis and tissue overgrowth. PIK3CA (acti-
vatingmutations of the p110a subunit of phosphatidylino-
sitol 3-kinases)-related overgrowth spectrum (PROS) is a
term used to describe a variety of clinical entities caused
by postzygotic mosaic mutations of the PIK3CA gene
that have hypertrophy of different parts of the body in
common.1 In general, PROS includes a heterogeneous
group of clinical overgrowth phenotypes and syndromes
such as congenital lipomatous overgrowth, vascular mal-
formations, epidermal nevi and spinal abnormalities
(CLOVES) syndrome,1 Klippel-Trenaunay syndrome
(KTS),2 fibroadipose overgrowth,3 hemimegalencephaly,4
macrodactyly,5 megalencephaly-capillary malformation,6
hemihyperplasia multiple lipomatosis, facial infiltrating
lipomatosis,7 and capillary malformation of the lower lip,
lymphaticmalformation of the face and neck, asymmetry
of the face and limbs, and partial or generalized
overgrowth8 (Fig 1).
PROS is an umbrella term for a heterogeneous mix of
syndromic diseases. Each presents with different clinical
symptoms and signs that can be more or less disabling
to the patient. Therefore, symptomatic and patient-
centered management and treatment approaches are
needed. The current established treatment modalities
include surgical (ie, corrective surgery, lesion debulking,
amputation) and interventional (ie, embolization of
vascular malformation) approaches or a combination of
both. Lately, pharmacologically targeted therapies to
inhibit the phosphatidylinositol-3-kinase (PI3K)/mamma-
lian target of rapamycin (mTOR) pathway have been
shown to be efficient and safe in reducing overgrowth
in patients with PROS.9 However, they are associated
with an impairment of the immune system and have he-
matologic, metabolic and gastrointestinal side effects.10
In thepresent study,weevaluated theefficacy and safety
of current overgrowth treatment modalities for patients
with PROS by performing a systematic review of the cur-
rent literature. We included randomized controlled
trials (RCTs), cohort studies, cross-sectional studies, case
control studies, and case series with $10 patients.11,12
METHODS
The present systematic review was conducted in accor-
dance with the PRISMA (preferred reporting items for
systematic reviews and meta-analyses) 2020 statement
guidelines.
Literature search. A professional medical information
specialist (W.M.B.) developed a systematic search strat-
egy to identify data concerning therapy regimens in
PROS, which was updated by a second professional
medical information specialist (B.M.). EMBASE, MEDLINE
(Ovid), Web of Science Core Collection, Cochrane Central
Register of Controlled Trials, ClinicalTrials.gov, andGoogle Scholar were last searched on February 13, 2021.
The aims of the search were to identify all studies of orig-
inal research data from human studies on the treatment
(including all treatment modalities; eg, surgical, pharma-
cological, or other) of PROS. The full search strategies for
all the databases are provided in the Appendix.
The study protocol was registered on PROSPERO
(PROSPERO 2020 CRD42020185010) before the begin-
ning of data extraction. No approval from the local ethics
committee was required, because our study was a sys-
tematic review of previously reported data via the stated
databases.
Selection of included studies. The references were im-
ported using EndNote, and duplicates were removed
using the method described by Bramer et al.13 Using
Endnote with themethod reported by Bramer et al,14 two
reviewers independently screened titles and abstracts for
eligibility. In the case of disagreement on the inclusion of
an abstract, a third author made the final decision for
inclusion. Likewise, eligible full-texts were assessed by two
reviewers independently, with the third author providing
the final decision in case of disagreement.
Inclusion and exclusion criteria. Other than prespeci-
fied in the PROSPERO protocol, we decided to include
only studies that had encompassed a definite reduction
of overgrowth of one or more parts of the body. Studies
were included if they (1) were cross-sectional, prospec-
tive, RCT, or case series of$10 patients; (2) included PROS
patients diagnosed genetically or clinically; (3) had
Fig 1. Overview of the most common clinical presentations, features, and PIK3CA (activating mutations of the
p110a subunit of phosphatidylinositol 3-kinases)-related overgrowth syndrome (PROS) syndromes. Created with
BioRender (available at: biorender.com).
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ment aimed at reducing hypertrophy; and (4) had
collected information on efficacy and safety outcomes.
Efficacy outcomes included the extent of overgrowth
definedby imaging studies or the clinical presence before
and after therapy and general symptom and pain relief
(eg, visual analog scale, Eastern Cooperative Oncology
Group, Karnofsky performance scale, quality of life [QOL]),
and the safety outcomes included any serious adverse
event or side effect reported in association with the
treatment.
The exclusion criteria were case reports or case series
with <10 patients owing to the very high risk of reporting
bias in those study types,12,15 noneEnglish and
noneGerman language studies, studies that had not per-
formed any treatment, and guideline and overview
studies without original research data. If full texts could
not be found online but were potentially eligible based
on the title and abstract, the corresponding authors
were contacted directly. Studies were excluded when
they were not accessible even via document delivery ser-
vices. Older studies were excluded if both reviewers
agreed independently that the study provided defini-
tions of PROS that were no longer up to date, accordingto the current International Society for the Study of
Vascular Anomalies classification and thus were
potentially not representative of the populations of inter-
est in our review (eg, KTS vs Klippel-Trenaunay-Weber
syndrome).
The corresponding authors of the reports that had
included PROS patients in the study population (eg low
flow venous malformations, including patients with KTS)
but had not reported the outcome stratified for the sub-
group of interest (PROS) were contacted via e-mail and
asked for additional specific outcome data on the PROS
patients. If such information was not provided within
1 month, the study was excluded.
Data extraction of included studies. Studies were eval-
uated according to their described treatment modality
in the pharmacologic, surgical, or interventional cate-
gories. The extracted data included study type, PROS
type studied, the overgrowth-affected body area, symp-
toms that had led to the described treatment, treatment
details, and outcome data (ie, improvement or wors-
ening of signs and symptoms, number of interventions,
length of follow-up, assessment of outcome [eg, radio-
logic imaging, self-report, clinical judgment of treating
Fig 2. PRISMA (preferred reporting items for systematic reviews and meta-analyses) flow diagram for the
systematic review of literature.
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treatment were extracted.
Assessment of risk of bias. To assess the risk of bias
(RoB), we used the Newcastle-Ottawa scale (NOS) for
cohort studies16 as prespecified, assessed by two re-
viewers independently. The RoB was considered low if
the NOS score was 8 to 9 stars, moderate for NOS score
was 5 to 7 stars, and high if the NOS score was #4 stars as
recommended by Wells et al.16 The limitations of this
three-dimensional score include assessment of selection
of the exposed and unexposed cohort, comparability of
the two cohorts, and outcomes assessment.17,18Statistical analysis. Categorical variables are presented
as percentages or absolute numbers. Continuous vari-
ables are presented as the mean 6 standard deviation.
Owing to the limited number of studies with data and
the heterogeneous definition of the medical input pa-
rameters, it was not feasible to pool the results and
perform a meta-analysis.RESULTS
Results from the literature search. The literature search
revealed 4592 titles and abstracts. After removing the du-
plicates, the titles and abstracts of 2787 unique citations




























* 0 0 * 0 * * * ***** Moderate
Cerrato et al,21
2013
* 0 * * 0 * * 0 ***** Moderate
Parker et al,9
2019
* 0 * * 0 * * * ***** Moderate
Sandbank
et al,32 2019
* 0 0 * 0 * * * ***** Moderate
Ishida et al,27
1998
* * * * * * * * ******** Low
Topoleski
et al,26 1997
* 0 * * 0 * * 0 ***** Moderate
Raab et al,31
2001
* * * * * * * * ******** Low
Padwa et al,30
2001
0 0 * * 0 * * * ***** Moderate
Kim et al,25
2015
* * * 0 * * * 0 ******* Moderate
Jacob et al,19
1998
* * * 0 * 0 * 0 ***** Moderate
Hardwicke
et al,20 2013
* * * * ** 0 * 0 ******* Moderate
Grogan et al,24
1991
* 0 * * 0 * 0 0 **** High
Chang et al,22
2002
* 0 * * * * * * ******* Moderate
Chen et al,23
1997
* 0 * * 0 * * 0 ***** Moderate
Couto et al,29
2015
0 0 * * 0 * * 0 **** High
Kotwal et al,28
1998
0 0 * * 0 * * * ***** Moderate
RoB, Risk of bias.
RoB was considered high if #4*, moderate 5-7*, low 8-9*. Representativeness of the exposed cohort: * given for truly or somewhat representative of the
average individual in the concerned community; Selection of the non-exposed cohort: * given for drawn from the same community as the exposed
cohort; Ascertainment of exposure: * given for secure record (eg surgical records) or structured interview; Demonstration that outcome of interest was
not present at start of study: * given if yes; Comparability: * given for any factor controlled for and an additional * for any additional factors; Ascer-
tainment of exposure: * given for independent blind assessment or record linkage; Follow-up long enough for outcomes to occur: * given if yes;
Adequacy of follow up: * given if complete follow up or subjects lost to follow up unlikely to introduce bias (<5%) or description provided of those lost).
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ports (Fig 2).
We had sent an e-mail to 16 authors for additional data
on studies to be considered for inclusion. However, no
additional data could be collected. Only one study had
presented interventional, surgical, and conservative treat-
ment options.19 Of the 240 studies, 25 had presented
interventional treatment methods; however, their aim
was mainly to address symptom control and not to
assess the reduction of overgrowth. Thus, these were
not included in the qualitative analysis. Treatment mo-
dalities aimed directly at reducing overgrowth of the
affected body part were found in 16 studies, which
were included in the final qualitative analysis (Fig 2).
Description of included studies. Of the 16 included
studies, overgrowth was treated surgically in 13(81.3%)19-31 and pharmacologically in 3 (18.7%).9,32,33 A to-
tal of 351 patients, aged from birth to 83 years, were
included and treated for hypertrophy. In three studies
(18.7%), the diagnosis of PROS was determined using a
genetic (nonclinical) definition for 58 patients. Accord-
ingly, for most of the included studies (81.3%), PROS was
defined using the clinical criteria of the associated syn-
dromes and/or radiologic documentation of overgrowth
and associated vascular anomalies (Fig 1).
The studies included in the present systematic review
included 12 retrospective medical record reviews (75%),
one retrospective audit (6.3%; in which outcome data
had been collected prospectively after the intervention
at a specific follow-up point),20 and 3 prospective cohort
studies (18.7%). The RoB was low for 2 studies (12.5%),
moderate for 12 studies (75%), and high for 2 studies
(12.5%; Table I).
Table II. Overview of included studies on surgical treatment
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“better,” n ¼ 30; “same,”
n ¼ 1; “worse,” n ¼ 1
Complications, n ¼ 16
in 66 surgeries:
superficial wound
infection, n ¼ 9; skin
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n ¼ 2; hypertrophic
scarring, n ¼ 2;
locking of a joint,
n ¼ 1
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Table II. Continued.
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(Continued on next page)
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DIP, Distal interphalangeal; KTS, Klippel-Trenaunay syndrome; MCP, metacarpophalangeal; MTP, metatarsophalangeal; NR, not reported; PIP,
proximal interphalangeal.
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trophy treatment in PROS (n ¼ 13; 81.25%) were reported
from 1991 to 2015.19-31 The included patients were either
pediatric patients only or a mix of pediatric and adult
patients. Among the PROS-associated syndromes, most
surgical treatment options were described for patients
with macrodactyly (nine studies; 69.3%). Five studies had
included patients with macrodactyly of the feet21,22,24-26
and three had included a mix of patients with macro-
dactyly of the feet and hands.20,23,28 Ishida et al27 reported
on surgical intervention of the hands only. The character-
istics of the included studies are presented in Table II.
Treatment was indicated for patients with macrodac-
tyly who were unable to wear the same-size shoes, those
with cosmetic impairment of the lower extremities, and
those with functional and cosmetic impairment of the
upper extremities. Pain was not reported. Treatment of
macrodactyly mainly consisted of debulking and ray
resection; however, epiphysiodesis and phalangeal
resection were also reported.
In five of nine studies (188 patients, aged from birth to
22 years), more than one operation was performed for
most patients, especially those with progressive over-
growth.20-23,28 The results generally appeared to be
better for those with static macrodactyly. The main
reported safety outcomes included hypertrophic
scarring and prolonged wound healing.
Two studies reported surgery for patients with KTS to
treat leg length differences with epiphysiodesis (n ¼ 46
patients).19,31 One study reported improvement in 80%
of the cases (n ¼ 41 patients).19 The other study reported
a postoperative leg length difference of <2 cm in two of
five cases and contralateral overgrowth of 2 to 5 cm in
three of five KTS patients. The reported complicationsincluded loosening of epiphyseal staples, wound healing
problems, and overcorrection with consecutive longitu-
dinal undergrowth of the treated leg.
Couto et al29 reported liposuction of the hypertrophic
parts of the body (trunk, upper and lower extremities,
face) in different PROS entities (17 patients; aged 2-
34 years) reducing the size, with improved function
and QOL in all patients and no further side effects.
Padwa and Mulliken30 reported surgical resection of
hypertrophic facial anomalies in 13 patients with fibroa-
dipose overgrowth (age, 1-22 years). However, little to
no benefit was found in the correction of facial asymme-
try and recurring hypertrophy after follow-up. In 3 pa-
tients, an elevation of the ipsilateral eye socket
occurred as a complication of surgery.30 Because of the
retrospective study design, 12 of the 13 studies did not
report prespecified safety outcomes. An overview of
included studies on surgical treatment for PROS is
presented in Table II.
Pharmacologic studies. All three studies reporting on
pharmacologic interventions included patients with
genetic data on PIK3CA mutations. PROS patients
included those who had presented with syndromic
mosaic mutations in the context of CLOVES, KTS,
megalencephaly-capillary malformation, and localized
overgrowth syndromes involving different parts of the
body.
Parker et al9 and Sandbank et al32 reported on the use of
sirolimus (rapamycin), an mTOR inhibitor with a macro-
lide structure that is given either orally or topically. The pa-
tients had presented with hypertrophy of one or more
parts of the body. None of the patients had presented
with isolated hypertrophy but had presented with more
Table III. Overview of included studies of medical treatment
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I), n ¼ 3; transient
hyperglycemia
(dietary control), n ¼ 1;
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antidiabetic
medication, n ¼ 1
(diabetic)
AEs, Adverse effects; ALT, alanine aminotransferase; CLOVES, congenital lipomatous overgrowth, vascular malformations, epidermal nevi and spinal
abnormalities; KTS, Klippel-Trenaunay syndrome; PROS, PIK3CA (activating mutations of the p110a subunit of phosphatidylinositol 3-kinases)-related
overgrowth spectrum; SAEs, serious adverse effects.
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pain, bleeding, and localized intravascular coagulation at
baseline. Parker et al9 reported a significant reduction in
the overgrown target lesions (e7.2%6 16.0%; P¼ .04) after
26 weeks of systemic sirolimus therapy with a target level
of 2 to 6 ng/mL. However, no significant improvement in
QOL occurred in their 39 patients (age, 3-48 years). Sand-
bank et al32 reported on seven patients with PROS within
their study population (36.8%). Of the seven patients, six
been treated with oral (two patients with CLOVES and
four patients with KTS) and one patient with KTS had
been treated with topical sirolimus. They reported near
complete resolution of cystic hemolymphatic malforma-
tions of the chest wall and limb overgrowth in one patient
with CLOVES (14.3%) after 22 months of sirolimus treat-
ment. One patient (14.3%) did not respond to treatment,
and five patients (71.4%) experienced partial resolution oftheir baseline symptoms, including the KTS patient with
topical sirolimus treatment.
Adverse events occurred in 4 of 7 patients (57%)32 and
28 of 39 patients (72%),9 respectively. The incidence of
serious adverse events (SAEs) was 21%.9 These included
bacterial and/or viral infections, blood count disorders,
elevated liver enzymes, and pulmonary embolism in
one patient reported by Parker et al.9 In the study sub-
group reported by Sandbank et al,32 only mild side ef-
fects had occurred (Table III). The reported side effects
included infection, hypercholesterolemia, liver enzyme
elevation, mouth sores, thrombocytopenia, neutropenia,
interstitial pneumonitis, hypersensitivity syndrome, pro-
longed fever, and abdominal pain.
The third study, by Venot et al,33 reported the use of
alpelisib (BYL179) in a cohort of 17 patients with PROS.
A response to treatment was noted in 100% of the
10 Bernhard et al Journal of Vascular Surgery: Venous and Lymphatic Disorders
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12.6% 6 3.8% and 16.3% 6 3.9% after 3 and 6 months of
treatment, respectively. The patients had received an
initial dose of 50 to 250 mg once daily, without any de-
tails on dose adjustments. Side effects occurred in
29.4% of patients, with only mild adverse events and no
serious adverse events were reported. An overview of
the included studies on pharmacological treatment, out-
comes, and side effects in PROS is presented in Table III.
DISCUSSION
In the present systematic review, we identified 16
studies reporting treatment to reduce overgrowth and
hypertrophy in patients with PROS. Our main findings
were, first, that therapy regimens with the aim to reduce
hypertrophy in PROS are mostly surgical, with the results
limited to local outcomes. Second, promising results
have been shown with pharmacologic PIK3CA inhibition.
However, the existing evidence for the treatment of
PROS is limited, and considerable RoB was present.
Finally, PROS was defined by a PIK3CA gene mutation
in only 18.7% of the included studies.
Surgical approaches seem beneficial for patients with
macrodactyly. However, as reported by Padwa and Mul-
liken,30 surgery does not seem to be effective for patients
with fibroadipose overgrowth, both (macrodactyly and
fibroadipose overgrowth) clinically categorized as
PIK3CA associated overgrowth syndromes. No data con-
cerning surgical treatment on other PROS types have
been reported other than in the form of case reports or
small case series (and were, thus, excluded from the pre-
sent review). Additionally, patients with stable, nonpro-
gressive (static) macrodactyly were included in addition
to those presenting with progressive macrodactyly. To
the best of our knowledge, the underlying mechanism
between static and progressive macrodactyly is not
well understood.
Kuentz et al34 were able to show that in 66.7% of iso-
lated and syndromic overgrowth presentations, a patho-
genic PIK3CA mutation was found using next generation
sequencing, with a greater prevalence in those with
syndromic overgrowth (74.0%) compared with those
with isolated overgrowth (35.5%). Therefore, no clear
statement concerning surgical therapy for PIK3CA-
associated overgrowth identified via PIK3CA mutations
is possible from the present data, because the disease
was diagnosed using clinical judgment alone.
Three trials provided data on targeted therapies
(PIK3CA inhibition with oral or topical sirolimus and
alpelisib). Sirolimus in the context of vascular anomalies
has been used with target plasma concentrations of
10.0 to 15.0 ng/mL, considered “high dose,”35 and 2 to
5 ng/mL, considered “low dose.”9 The current practice
is to start with a “low dose,” although this has not been
included in a guideline. More difficult has been to pro-
pose the optimal duration for this experimental therapy,especially if the patient experiences a response. In such
cases, sirolimus can be administered without a time lim-
itation. However, to the best of our knowledge, data on
the long-term effects and toxicity are missing. The
included studies, however, also did not provide any in-
formation regarding the decision to use oral vs topical
therapy. Individually targeted therapy based on the
identification of tumor oncogenes is an established
treatment option to reduce tumor growth. Therapy tar-
geting the expression of genetic variants is effective, not
only in the treatment of vascular tumors,36 but could
also become an option for patients with congenital
vascular malformations and PROS.10,37 Identifying the
mosaic mutation in PROS patients has been difficult in
the past because polymerase chain reaction or Sanger
sequencing missed PIK3CA mutations owing to the
mosaic and low-abundant nature in PROS patients.38,39
However, with the initiation of next generation
sequencing, it became possible to identify mutations
with low-level expression of mosaicism variants. Thus,
future studies might identify additional mosaic muta-
tions in PROS patients that can aid in targeted
therapies.
Implications and future perspectives. The findings
from our literature review have revealed the current
lack of evidence concerning the reduction of hypertro-
phy in PROS. However, evidence from prospective cohort
studies on the use of repurposed drugs from other indi-
cations has suggested that a genetically targeted treat-
ment approach could lead to improvements in the
treatment and permanent reduction of hypertrophy in
these patients. The diagnosis of PROS should be
confirmed by genetic analyses of PIK3CA mutations,
among other potential genes, allowing for targeted treat-
ment and improved outcomes for these patients.
Ongoing trials testing drugs that target PIK3CA path-
ways, including sirolimus,40 ARQ 092,41 and alpelisib.42
A trial using taselisib (TOTEM [trial of taselisib in over-
growth]) was recently stopped early for safety reasons
after two suspected unexpected serious adverse re-
actions occurred.43 Additionally, because PROS is rare,
international collaborations are needed to advance the
research in this field, to have sufficient numbers of
patients in larger, prospective cohort studies and/or
RCTs, and to increase support for genetic-based
diagnosis and targeted treatments.
Study limitations. The present study was not without
limitations. Although our initial aim was to perform a
meta-analysis to derive estimates to determine the
magnitude and strength of evidence present for the
treatment of PROS, a meta-analysis was not feasible
owing to insufficient data from the RCTs. Because the
terminology for, and definition of, PROS were very
inconsistent before the International Society for the
Journal of Vascular Surgery: Venous and Lymphatic Disorders Bernhard et al 11
Volume -, Number -Study of Vascular Anomalies definition was established,
it was impossible to include studies performed before
the 1990s. Because most of the included studies had
defined PROS from the clinical findings, it remains
unknown how many of the included patients had had a
PIK3CA mutation, a very important limitation to our
review.
Another major problem of the present analysis was the
limited data concerning the safety and QOL owing to the
mainly retrospective study design without predefined
safety assessments. Furthermore, QoL assessments were
performed using generic, nonedisease-specific QoL in-
struments, because disease-specific QoL measuring tools
for these types of vascular malformations do not exist.
CONCLUSIONS
Surgical options will be beneficial for a specific sub-
group of patients with PROS (ie, those with macrodac-
tyly). However, little evidence is available regarding
surgery for other PROS entities. Direct PIK3CA inhibition
has been emerging as a promising treatment option for
PROS patients. However, evidence is missing from ran-
domized controlled trials concerning efficacy and, more
importantly, safety issues. Additionally, a more system-
atic, genetic definition of PROS using next generation
sequencing is needed across populations. International
collaborations are also required to address these areas
of limited evidence to gather sufficient patient numbers
to study these rare diseases.
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Database for literature search
Embase, Medline, Web of Science Core Collection,
Cochrane CENTRAL register of trials
Search criteria
Patients: all patients with PIK3CA (activating mutations
of the p110a subunit of phosphatidylinositol 3-kinases)-
related overgrowth spectrum (PROS)
Intervention: any of treatment modalities listed:
Pharmacotherapy: mammalian target of rapamycin
(mTOR) inhibitors, AKT inhibitors, phosphatidylinosi-
tol-3-kinase (PI3K) inhibitors (metformin, aspirin)
Surgery: removal of target lesion, debulking





1. Extension of malformation before and after treatment
on vascular imaging or clinical presentation
2. General symptom relief and pain reduction (visual
analog scale, Eastern Cooperative Oncology Group,
Karnofsky performance scale, quality of life)
Safety
1. Any adverse event, adverse effect, or side effect or
serious adverse event, adverse effect or side effect re-







Case reportsSearch results from May 20, 2020
Results
Results after removal of
duplicates
Embase.com 1476 1453







Total 3120 1767Search strategy
Embase.com, n ¼ 1948
(’pik3ca related overgrowth spectrum’/de OR ((’pik3ca
gene’/de OR ’Pi3K/Akt signaling’/de OR ’phosphatidyli-
nositol 4,5 bisphosphate 3 kinase’/de OR ’phosphatidy-
linositol 3 kinase’/de) AND (’overgrowth syndrome’/de
OR ’congenital blood vessel malformation’/de)) OR
((’hemihyperplasia’/de OR ’face’/de OR ’face asymme-
try’/de OR ’face tumor’/exp) AND ’lipomatosis’/de) OR
’cloves syndrome’/de OR ’macrodactyly’/de OR (’Alex-
ander disease’/de AND (’capillary malformation’/de
OR ’cutis marmorata telangiectatica congenita’/de))
OR ’angioosteohypertrophy syndrome’/de
OR (((Fibroadipose OR Fibro-adipose) NEAR/3 (hyper-
plasia OR overgrowthOR vascul*-anomal*)) OR ((hemi-
hyperplas* OR hemi-hyperplas*) NEAR/3 lipomatosis)
OR (Congenital NEAR/3 Lipomat* NEAR/3 Overgrow*)
OR (cloves NEAR/3 syndrome*) OR (Vascular NEAR/6
(Nevi OR nevus) NEAR/6 Scoliosis NEAR/6 (Skelet* OR
Spin*)) OR macrodactyl* OR ((Facial OR face*) NEAR/6
(infiltrat* OR infuse*) NEAR/6 Lipomatosis) OR (Mega-
lencephal* NEAR/6 capilla* NEAR/3 (congenital* OR
malform*)) OR (Dysplast* NEAR/3 Megalencephal*)
OR (Klippel NEAR/3 Trenaunay) OR angioosteohyper-
troph* OR angio-osteohypertroph* OR angioosteo-
hypertroph* OR angio-osteo-hypertroph* OR (heman-
giect* NEAR/3 hypertroph*) OR ((pik3ca OR pik3-ca
OR pik-3ca OR pik-3-ca OR PI3K OR PI-3K OR PI3-K
OR PI-3-K) NEAR/6 (overgrow* OR vessel* OR vascular))
OR fava OR pros-syndrome*):ab,ti) AND (’mammalian
target of rapamycin inhibitor’/exp OR ’mammalian
target of rapamycin’/exp OR ’protein kinase B inhibi-
tor’/exp OR ’protein kinase B’/exp OR Metformin/de
OR ’acetylsalicylic acid’/de OR ’drug therapy’/de OR
’surgery’/de OR ’cytoreductive surgery’/de OR ’artificial
12.e2 Bernhard et al Journal of Vascular Surgery: Venous and Lymphatic Disorders
--- 2021embolization’/exp OR ’sclerotherapy’/exp OR ’low level
laser therapy’/de OR (((mtor OR protein-kinase OR akt
ORPI3K)NEAR/3 (inhibit*OR inactivat*))OR rapamycin
ORsirolimusORMetformin*ORacetylsalic*ORaspirin*
OR (drug* NEAR/3 therap*) OR Pharmacotherap* OR
surger* OR surgical* OR surgeon* OR remov* OR
debulk* OR cytoreduct* OR embolizat* OR embolisat*
OR sclerotherap* OR laser* OR therap* OR treat*
OR intervent*):ab,ti)
Medline Ovid, n ¼ 1376
(((exp Phosphatidylinositol 3-Kinases/) AND (exp
Blood Vessels/ab)) OR ((Hemihyperplasia, Isolated.rx.
OR exp Face/ OR exp Facial Neoplasms/) AND exp
Lipomatosis/) OR Megalodactyly.nm. OR (Alexander
Disease/ AND (Capillaries/ab OR Cutis marmorata
telangiectatica congenital.rx.)) OR angioosteohyper-
trophy syndrome/ OR (((Fibroadipose OR Fibro-
adipose) ADJ3 (hyperplasia OR overgrowth OR vas-
cul*-anomal*)) OR ((hemihyperplas* OR hemi-hyper-
plas*) ADJ3 lipomatosis) OR (Congenital ADJ3
Lipomat* ADJ3 Overgrow*) OR (cloves ADJ3 syn-
drome*) OR (Vascular ADJ6 (Nevi OR nevus) ADJ6
Scoliosis ADJ6 (Skelet* OR Spin*)) OR macrodactyl*
OR ((Facial OR face*) ADJ6 (infiltrat* OR infuse*)
ADJ6 Lipomatosis) OR (Megalencephal* ADJ6 capilla*
ADJ3 (congenital* OR malform*)) OR (Dysplast* ADJ3
Megalencephal*) OR (Klippel ADJ3 Trenaunay) OR
angioosteohypertroph* OR angio-osteohypertroph*
OR angioosteo-hypertroph* OR angio-osteo-hyper-
troph* OR (hemangiect* ADJ3 hypertroph*) OR
((pik3ca OR pik3-ca OR pik-3ca OR pik-3-ca OR PI3K
OR PI-3K OR PI3-K OR PI-3-K) ADJ6 (overgrow* OR
vessel* OR vascular)) OR fava OR pros-syndro-
me*).ab,ti.) AND (TOR Serine-Threonine Kinases/ OR
Proto-Oncogene Proteins c-akt/ OR Metformin/ OR
Aspirin/ OR Drug Therapy/ OR Surgical Procedures,
Operative/ OR surgery.fs. OR Cytoreduction Surgical
Procedures/ OR Embolization, Therapeutic/ OR
Sclerotherapy/ OR Low-Level Light Therapy/ OR
(((mtor OR protein-kinase OR akt OR PI3K) ADJ3
(inhibit* OR inactivat*)) OR rapamycin OR sirolimus
OR Metformin* OR acetylsalic* OR aspirin* OR (drug*
ADJ3 therap*) OR Pharmacotherap* OR surger* OR
surgical* OR surgeon* OR remov* OR debulk* OR
cytoreduct* OR embolizat* OR embolisat* OR sclero-
therap* OR laser* OR therap* OR treat* OR
intervent*).ab,ti.)
Web of Science core collection, n ¼ 1124
TS¼(((((Fibroadipose OR Fibro-adipose) NEAR/2 (hy-
perplasia OR overgrowth OR vascul*-anomal*)) OR
((hemihyperplas* OR hemi-hyperplas*) NEAR/2 lipo-
matosis) OR (Congenital NEAR/2 Lipomat* NEAR/2
Overgrow*) OR (cloves NEAR/2 syndrome*) OR
(Vascular NEAR/5 (Nevi OR nevus) NEAR/5 Scoliosis
NEAR/5 (Skelet* OR Spin*)) OR macrodactyl* OR((Facial OR face*) NEAR/5 (infiltrat* OR infuse*)
NEAR/5 Lipomatosis) OR (Megalencephal* NEAR/5
capilla* NEAR/2 (congenital* OR malform*)) OR
(Dysplast* NEAR/2 Megalencephal*) OR (Klippel
NEAR/2 Trenaunay) OR angioosteohypertroph* OR
angio-osteohypertroph* OR angioosteo-hypertroph*
OR angio-osteo-hypertroph* OR (hemangiect*
NEAR/2 hypertroph*) OR ((pik3ca OR pik3-ca OR
pik-3ca OR pik-3-ca OR PI3K OR PI-3K OR PI3-K
OR PI-3-K) NEAR/5 (overgrow* OR vessel* OR
vascular)) OR fava OR pros-syndrome*)) AND
((((mtor OR protein-kinase OR akt OR PI3K) NEAR/
2 (inhibit* OR inactivat*)) OR rapamycin OR siroli-
mus OR Metformin* OR acetylsalic* OR aspirin* OR
(drug* NEAR/2 therap*) OR Pharmacotherap* OR
surger* OR surgical* OR surgeon* OR remov* OR
debulk* OR cytoreduct* OR embolizat* OR emboli-
sat* OR sclerotherap* OR laser* OR therap* OR
treat* OR intervent*)))
Cochrane Central register of trials, n ¼ 36
((((Fibroadipose OR "Fibro-adipose") NEAR/3 (hyper-
plasia OR overgrowth OR vascul* NEXT anomal*))
OR ((hemihyperplas* OR hemi-hyperplas*) NEAR/3
(lipomatosis)) OR (Congenital NEAR/3 Lipomat*
NEAR/3 Overgrow*) OR (cloves NEAR/3 syndrome*)
OR (Vascular NEAR/6 (Nevi OR nevus) NEAR/6 Scoli-
osis NEAR/6 (Skelet* OR Spin*)) OR macrodactyl* OR
((Facial OR face*) NEAR/6 (infiltrat* OR infuse*)
NEAR/6 Lipomatosis) OR (Megalencephal* NEAR/6
capilla* NEAR/3 (congenital* OR malform*)) OR (Dys-
plast* NEAR/3 Megalencephal*) OR (Klippel NEAR/3
Trenaunay) OR angioosteohypertroph* OR angio-
osteohypertroph* OR angioosteo-hypertroph* OR
angio-osteo-hypertroph* OR (hemangiect* NEAR/3
hypertroph*) OR ((pik3ca OR "pik3-ca" OR "pik-3ca"
OR "pik-3-ca" OR PI3K OR "PI-3K" OR "PI3-K" OR "PI-
3-K") NEAR/5 (overgrow* OR vessel* OR vascular)) OR
fava OR pros-syndrome*):ab,ti) AND ((((mtor OR
protein-kinase OR akt OR PI3K) NEAR/3 (inhibit* OR
inactivat*)) OR rapamycin OR sirolimus OR Metfor-
min* OR acetylsalic* OR aspirin* OR (drug* NEAR/3
therap*) OR Pharmacotherap* OR surger* OR surgi-
cal* OR surgeon* OR remov* OR debulk* OR
cytoreduct* OR embolizat* OR embolisat* OR sclero-
therap* OR laser* OR therap* OR treat* OR
intervent*):ab,ti)
ClinicalTrials.gov (expert search), n ¼ 8
PIK3CA-related overgrowth spectrum
Google scholar: first 100 results (according to relevance
ranking)
"PIK3CA related overgrowth" FAVA "Congenital Lipo-
matous Overgrowth "CLOVES syndrome" Macrodac-
tyly "Facial Infiltrating Lipomatosis" "Capillary
Malformation" "Klippel-Trenaunay" therapy surgery
treatment
